Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
Deficiencies of lysosomal β-D-galactosidase can result in GM1 gangliosidosis, a severe neurodegenerative disease characterized by massive neuronal storage of GM1 ganglioside in the brain. Currently there are no available therapies that can even slow the progression of this disease. Enzyme enhancement therapy utilizes small molecules that can often cross the blood brain barrier, but are also often competitive inhibitors of their target enzyme. It is a promising new approach for treating diseases, often caused by missense mutations, associated with dramatically reduced levels of functionally folded enzyme. Despite a number of positive reports based on assays performed with patient cells, skepticism persists that an inhibitor-based treatment can increase mutant enzyme activity in vivo. To date no appropriate animal model, i.e., one that recapitulates a responsive human genotype and clinical phenotype, has been reported that could be used to validate enzyme enhancement therapy. In this report, we identify a novel enzyme enhancement-agent, N-nonyl-deoxygalactonojirimycin, that enhances the mutant β-galactosidase activity in the lysosomes of a number of patient cell lines containing a variety of missense mutations. We then demonstrate that treatment of cells from a previously described, naturally occurring feline model (that biochemically, clinically and molecularly closely mimics GM1 gangliosidosis in humans) with this molecule, results in a robust enhancement of their mutant lysosomal β-galactosidase activity. These data indicate that the feline model could be used to validate this therapeutic approach and determine the relationship between the disease stage at which this therapy is initiated and the maximum clinical benefits obtainable.
Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada M5G 1X8.
Brigitte A
BA
Rigat
Michael B
MB
Tropak
Justin
J
Buttner
Ellen
E
Crushell
Daphne
D
Benedict
John W
JW
Callahan
Douglas R
DR
Martin
Don J
DJ
Mahuran
D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002415:Cats; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D016537:Gangliosidosis, GM1 / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D006358:Hot Temperature; D006801:Humans; D006863:Hydrogen-Ion Concentration; D050505:Mutant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D009154:Mutation; D011489:Protein Denaturation / Q000187:drug effects; D016896:Treatment Outcome; D001616:beta-Galactosidase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*
D050505:Mutant Proteins; C112150:N-nonyl-1-deoxynojirimycin; D017485:1-Deoxynojirimycin; D001616:beta-Galactosidase